Condition
Lobular Carcinoma In Situ
Total Trials
6
Recruiting
0
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (2)
P 1 (1)
P 2 (3)
Trial Status
Completed2
Not Yet Recruiting1
Active Not Recruiting1
Terminated1
Withdrawn1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT02928978Phase 2Completed
Ruxolitinib for Premalignant Breast Disease
NCT07408856Phase 1Not Yet Recruiting
CAN1012 in Pre-Malignant DCIS and LCIS
NCT03868475Not ApplicableWithdrawn
Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions
NCT06033092Phase 2Active Not Recruiting
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
NCT02137252Phase 2Terminated
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
NCT00620087Not ApplicableCompleted
Molecular Breast Imaging in Women With Atypia and LCIS
Showing all 6 trials